EKF Diagnostics Holdings plc expected its results for the first half of 2015 to show unaudited revenues of £16.8 million, around the same level as last year, despite not having materially benefited from any tender wins in the current period. Unaudited adjusted EBITDA for the period will be around £0.7 million (in the first half of 2014: £2.2 million). This reduced level of earnings reflects the continuing impact of the investment in its Molecular division.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33 GBX | 0.00% | +8.91% | +4.27% |
05-15 | Future Metals celebrates state government grant | AN |
05-14 | EKF Diagnostics Holdings Says Q1 Adj EBITDA Shows About 20% Improvement | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.27% | 190M | |
-11.41% | 2.95B | |
-14.72% | 84.22M | |
+10.14% | 53.05M |
- Stock Market
- Equities
- EKF Stock
- News EKF Diagnostics Holdings plc
- EKF Diagnostics Holdings plc Provides Earnings Guidance for the Six Months Ended June 30, 2015